Pharma Tech

IDWeek 2026: despite missing primary endpoint, LB6V shows promise in Lyme disease

Oct 28, 2026, 2:00 PM

Read Full Article → IDWeek 2026: despite missing primary endpoint, LB6V shows promise in Lyme disease

Translate article text

Choose a language and wait for the translated text.

The commercial opportunity for a prophylactic Lyme disease vaccine in the US and Europe is substantial. LB6V is well placed to capitalise on this gap.